- Study: Daily aspirin use may reduce risk of ovarian cancer by 20%
- ROUNDTABLE: Pharmacy’s future in sync with technology
- CVS Caremark to stop selling tobacco in all store locations
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- EXPERT BLOG: Provider status for pharmacists — one way or another
SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched its new chemotherapy drug.
Sagent sent that its paclitaxel injection USP is available in 30-mg, 100-mg and 300-mg latex-free, multi-dose vials. Paclitaxel is indicated for use alone or with other drugs to treat ovarian cancer, breast cancer, non-small cell lung cancer and AIDS-related Kaposi's sarcoma, Sagent said.
"Paclitaxel is currently on the American Society of Health-System Pharmacists' and the U.S. [Food and Drug Administration] drug shortage lists and we are pleased to be able to help supply this vital chemotherapy option to patients," Sagent founder, board chairman and CEO Jeffrey Yordon said. "The launch of paclitaxel expands our rapidly growing portfolio of injectable oncolytics to six products."
U.S. market for generic injectable paclitaxel approximates $46 million, according to IMS Health data.